Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012257083> ?p ?o ?g. }
- W2012257083 endingPage "161" @default.
- W2012257083 startingPage "137" @default.
- W2012257083 abstract "Introduction: Glaucoma is a prevalent ocular disease with characteristic optic disc and visual field changes. Globally, it is the second most common cause of visual disability, and the most common cause of irreversible and preventable blindness. Ocular hypertension (OH) occurs where intraocular pressure elevation occurs in the absence of glaucomatous disc and visual field changes. OH is a strong risk factor for glaucoma. Ocular hypotensive medications are the mainstay of glaucoma and OH treatment, and their use modifies the course of the disease by preventing onset and progression of damage. Areas covered: Prostaglandin analogs, β-blockers, α-agonists, carbonic anhydrase inhibitors and parasympathomimetics are available in our glaucoma armamentarium and are reviewed. Novel agents have evolved as our understanding of the complex mechanisms involved in aqueous humor production and obstacles to aqueous outflow increases. Potential future candidates appear to act on enhancing trabecular meshwork outflow: the Rho-kinase inhibitors, ion-channel modulators and chelating agents. Further work is needed on other promising agents: serotonergics, melatonins, cannabinoids, adenosine agonists, components of the actomyosin system, nucleotide analogs and gene silencing. Methods to improve side effect profiles or efficacy of currently available therapies are also being developed. As glaucoma treatment adherence is poor, novel drug delivery methods might address this challenge. Expert opinion: Although there are good intraocular pressure-lowering medications available, novel mechanisms and drug delivery modes may provide more effective glaucoma control in future." @default.
- W2012257083 created "2016-06-24" @default.
- W2012257083 creator A5034006045 @default.
- W2012257083 creator A5077202285 @default.
- W2012257083 date "2011-02-25" @default.
- W2012257083 modified "2023-10-17" @default.
- W2012257083 title "Emerging drugs for ocular hypertension" @default.
- W2012257083 cites W115144196 @default.
- W2012257083 cites W1481720650 @default.
- W2012257083 cites W1490909919 @default.
- W2012257083 cites W1510328004 @default.
- W2012257083 cites W1549224984 @default.
- W2012257083 cites W1567036454 @default.
- W2012257083 cites W1573072429 @default.
- W2012257083 cites W1592657292 @default.
- W2012257083 cites W1595395957 @default.
- W2012257083 cites W1753089048 @default.
- W2012257083 cites W186252241 @default.
- W2012257083 cites W1936592935 @default.
- W2012257083 cites W1963827127 @default.
- W2012257083 cites W1964747407 @default.
- W2012257083 cites W1966093962 @default.
- W2012257083 cites W1966822289 @default.
- W2012257083 cites W1966910690 @default.
- W2012257083 cites W1967595191 @default.
- W2012257083 cites W1967968827 @default.
- W2012257083 cites W1967978506 @default.
- W2012257083 cites W1968169793 @default.
- W2012257083 cites W1968294179 @default.
- W2012257083 cites W1968812604 @default.
- W2012257083 cites W1970063550 @default.
- W2012257083 cites W1971086878 @default.
- W2012257083 cites W1971522144 @default.
- W2012257083 cites W1972275929 @default.
- W2012257083 cites W1973568125 @default.
- W2012257083 cites W1974104565 @default.
- W2012257083 cites W1975361674 @default.
- W2012257083 cites W1976253654 @default.
- W2012257083 cites W1976387869 @default.
- W2012257083 cites W1977730321 @default.
- W2012257083 cites W1978387164 @default.
- W2012257083 cites W1979495469 @default.
- W2012257083 cites W1979581271 @default.
- W2012257083 cites W1979590308 @default.
- W2012257083 cites W1979846948 @default.
- W2012257083 cites W1980315610 @default.
- W2012257083 cites W1981432028 @default.
- W2012257083 cites W1981684730 @default.
- W2012257083 cites W1981771045 @default.
- W2012257083 cites W1983398617 @default.
- W2012257083 cites W1984197291 @default.
- W2012257083 cites W1986248969 @default.
- W2012257083 cites W1986751457 @default.
- W2012257083 cites W1987069171 @default.
- W2012257083 cites W1987339421 @default.
- W2012257083 cites W1987984585 @default.
- W2012257083 cites W1988719910 @default.
- W2012257083 cites W1989399186 @default.
- W2012257083 cites W1989436655 @default.
- W2012257083 cites W1990379682 @default.
- W2012257083 cites W1990673243 @default.
- W2012257083 cites W1990813467 @default.
- W2012257083 cites W1991186732 @default.
- W2012257083 cites W1991360380 @default.
- W2012257083 cites W1991537059 @default.
- W2012257083 cites W1991653282 @default.
- W2012257083 cites W1992113895 @default.
- W2012257083 cites W1992927986 @default.
- W2012257083 cites W1993763188 @default.
- W2012257083 cites W1994121198 @default.
- W2012257083 cites W1994970293 @default.
- W2012257083 cites W1996754070 @default.
- W2012257083 cites W1997646447 @default.
- W2012257083 cites W2000180976 @default.
- W2012257083 cites W2000447068 @default.
- W2012257083 cites W2001876659 @default.
- W2012257083 cites W2001985437 @default.
- W2012257083 cites W2003535585 @default.
- W2012257083 cites W2003916074 @default.
- W2012257083 cites W2004102565 @default.
- W2012257083 cites W2007224070 @default.
- W2012257083 cites W2007937948 @default.
- W2012257083 cites W2010179280 @default.
- W2012257083 cites W2010581694 @default.
- W2012257083 cites W2010755453 @default.
- W2012257083 cites W2011188352 @default.
- W2012257083 cites W2011777530 @default.
- W2012257083 cites W2012360020 @default.
- W2012257083 cites W2012624430 @default.
- W2012257083 cites W2013470532 @default.
- W2012257083 cites W2014393917 @default.
- W2012257083 cites W2014449931 @default.
- W2012257083 cites W2017222966 @default.
- W2012257083 cites W2017227447 @default.
- W2012257083 cites W2017879197 @default.
- W2012257083 cites W2018071295 @default.
- W2012257083 cites W2018408210 @default.
- W2012257083 cites W2018730233 @default.